All Articles

A critical safety milestone for PepGen’s PGN-EDODM1 offers a glimmer of hope for myotonic dystrophy patients and highlights a novel strategy in a competitive field.

The industrial giant just posted record sales and profits. We go beyond the headlines to see how strategic acquisitions are setting the stage for even more ambitious growth.

Follett Software embeds AI into its K-12 platform at no cost, promising efficiency. But a closer look reveals a strategy that may reshape EdTech budgets.

Priority Technology reports impressive revenue growth, yet its GAAP profits are falling. A deep dive into the fintech's complex financials reveals its strategy.

As a major cyclospora outbreak sweeps the U.S., Roche's new research-only PCR tests provide a critical, behind-the-scenes tool for public health.

Lummus Technology's acquisition of Shell's emissions control unit is more than a simple transaction; it's a calculated move to dominate the industrial decarbonization market.

Rare Beauty Brands and JCPenney's LIFT accelerator isn't just about funding; it's a systemic blueprint for diversifying an industry from the ground up.

Pollo AI's new Agent 2.0 moves beyond simple generation, acting as an intelligent coordinator for video production. Is this the future of marketing content?

Facing crippling new U.S. tariffs, a Canadian brand isn't just surviving—it's building a coalition. Miik's "Keep it Canadian" challenge is a masterclass.

NexPoint thrives amid credit market turmoil by pairing cycle-resistant assets with a high-yield lending offensive, revealing a durable model for value creation.

While others chase scale, Netgain proves that deep expertise in regulated sectors like healthcare and legal is the key to sustained growth and industry leadership.

MacPaw's Moonlock didn't just win; it swept the Stevie Awards. This triple victory for its team, talent, and tech reveals a deeper strategy for Mac users.

As AI adoption outpaces governance, a new firm is creating a credit score-like system for AI risk. With a high-powered advisory board, is this the key to resilience?

With the launch of its TED drug Lumvoa, Viridian Therapeutics steps into the commercial ring. But can early momentum and a deep pipeline justify the cost?

A "Product of the Year" award for a dog treat is more than just news. It reveals a deep shift in corporate strategy and the growing pet wellness system.

With a 32% jump in royalty revenue and a game-changing acquisition, Ligand Pharmaceuticals solidifies its market dominance. But is the growth sustainable?

Gogo's Q2 results show a net loss, but a 40% surge in military revenue is funding its critical, costly transition to next-gen Galileo and 5G services.

A strategic hire at RegTech firm RiskExec reveals a new reality: AI is no longer just a tool, but a core strategy for navigating financial regulation.

With $60M in new funding and veteran pharma execs on board, Vedanta Biosciences is set for the pivotal last leg of its Phase 3 trial for VE303.

The payment tech firm posts record cash flow and raises guidance, but a closer look reveals a story of strategic acquisitions and uneven performance.